SLC6A20

Across TCGA pan-cancer cohorts, SLC6A20 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SLC6A20’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SLC6A20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC6A20 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

COAD, KIRC, and LUSC are the cancer types where SLC6A20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	+2.281	<.001	10	view →
KIRC	Male	III,IV	−1.457	<.001	9	view →
LUSC	Female	II,III,IV	−2.810	<.001	8	view →
THCA	All	II,III,IV	+1.714	<.001	8	view →
KICH	All	II,III,IV	−1.212	.004	8	view →
UCEC	All	All	+1.280	.001	6	view →
BRCA	Female	II,III,IV	+0.208	.008	4	view →
ESCA	All	II,III,IV	+3.814	.009	3	view →
LUAD	Female	All	−1.208	<.001	3	view →
KIRP	Male	All	+2.014	<.001	2	view →
STAD	Male	All	+1.247	.046	2	view →
LIHC	Female	II,III,IV	−0.104	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SLC6A20–COAD

Open the COAD breakdown →